Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Martin E. Gore, Subramanian Hariharan, Camillo Porta, Sergio Bracarda, Robert Hawkins, Georg A. Bjarnason, Stéphane Oudard, Se Hoon Lee, Giacomo Carteni, Alejandra Nieto, Jinyu Yuan, Cezary Szczylik

    Research output: Contribution to journalArticlepeer-review


    Background: In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open-label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. Methods: Previously treated and treatment-naive metastatic RCC patients ≤ yen;18 years received sunitinib 50 mg orally, once daily, on Schedule 4/2. Safety was assessed regularly, tumor measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention-to-treat (ITT) population, consisting of all patients who received ≤ yen;1 dose of sunitinib. Results: As of December 2007, 4564 patients had enrolled in 52 countries. Of these enrollees, 4371 were included in the modified ITT population, of whom 321 (7%) had baseline brain metastases and had received a median of 3 treatment cycles (range 1-25). Reasons for their discontinuation included lack of efficacy (32%) and adverse events (8%). The most common grade 3-4 treatment-related adverse events were fatigue and asthenia (both 7%), thrombocytopenia (6%), and neutropenia (5%), the incidence of which were comparable to that for the overall EAP population. Of 213 evaluable patients, 26 (12%) had an objective response. Median progression-free survival and overall survival were 5.6 months (95% CI, 5.2-6.1) and 9.2 months (95% CI, 7.8-10.9), respectively. Conclusions: In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity. © 2010 American Cancer Society.
    Original languageEnglish
    Pages (from-to)501-509
    Number of pages8
    Issue number3
    Publication statusPublished - 1 Feb 2011


    • brain
    • expanded access program
    • metastases
    • renal cell carcinoma
    • sunitinib


    Dive into the research topics of 'Sunitinib in metastatic renal cell carcinoma patients with brain metastases'. Together they form a unique fingerprint.

    Cite this